IL1A and systemic sclerosis: The LIGHT trial (ClinicaL efficacy of Inhibition of orGan dysfunction througH bermekimab in systemic sclerosis: a proof-of-concept double-blind randomized clinical Trial) investigated the clinical efficacy of IL-1α inhibition in advanced SSc by bermekimab.